EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease

Jolanda M P Liefhebber, Giso Brasser, Elisabeth A Spronck, Roelof Ottenhoff, Lieke Paerels, Maria J Ferraz, Lukas K Schwarz, Nikoleta Efthymiopoulou, Chi-Lin Kuo, Paula S Montenegro-Miranda, Melvin M Evers, Johannes M F G Aerts und 1 weitere

Molecular Therapy - Methods & Clinical Development · 2024-12 · 32 (4) · 101375

DOI: 10.1016/j.omtm.2024.101375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy - Methods & Clinical Development, 2024-12. Verfasst von Jolanda M P Liefhebber und 12 weiteren Autor:innen. Beteiligte Einrichtung: uniQure biopharma B.V., Amsterdam 1105 BP, the Netherlands. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We developed a novel adeno-associated virus 5 gene therapy (AAV5-GLA) expressing human alpha-galactosidase A (GLA) under the control of a novel, small and strong, liver-restricted promoter. We assessed the preclinical potential of AAV5-GLA for treating Fabry disease, an X-linked hereditary metabolic disorder resulting from mutations in the gene encoding GLA that lead to accumulation of the substrates globotriaosylceramide and globotriaosylsphingosine, causing heart, kidney, and central nervous system dysfunction. Effects of intravenously administered AAV5-GLA were evaluated in (1) GLA-knockout mice aged 7-8 weeks (early in disease) and 20 weeks (nociception phenotype manifestation) and (2) cynomolgus macaques during an 8-week period. In both species, AAV5-GLA was observed as safe, generated detectable vector DNA and mRNA levels in liver, and produced stable enzyme activity in liver and plasma. In mice, dose-dependent transgene enzyme activity, cross-correction (substrate reduction) in kidney and heart, and improved nociception lasted over 6 months. Moreover, after delayed administration when animals displayed the nociception phenotype, target organ enzyme activity was present, and accumulated substrates were reduced. Given the strong, durable expression of active GLA with this promoter and favorable profile of adeno-associated virus 5-based gene therapy in humans, AAV5-GLA warrants further investigation in clinical trials for Fabry disease.

Schlagwörter

Stichwörter der Autor:innen

Macaca fascicularisX chromosomeglycosphingolipidsknockoutlysosomal storage diseasesmetabolismmicemutationnociceptionsphingolipidoses

Autor:innen und Institutionen

  • uniQure biopharma B.V., Amsterdam 1105 BP, the Netherlands.
  • Amsterdam UMC, Amsterdam 1105 AZ, the Netherlands.
  • Leiden Institute of Chemistry, Leiden University, Leiden 2333 CC, the Netherlands.
  • VIB, 9052 Ghent, Belgium.
  • VectorY Therapeutics B.V., Amsterdam 1098 XH, the Netherlands.

Zitieren

APA

Liefhebber, J. M. P., Brasser, G., Spronck, E. A., Ottenhoff, R., Paerels, L., Ferraz, M. J., Schwarz, L. K., Efthymiopoulou, N., Kuo, C. L., Montenegro-Miranda, P. S., Evers, M. M., Aerts, J. M. F. G., & Liu, Y. P. (2024). Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease. Molecular Therapy - Methods & Clinical Development, 32(4), 101375. https://doi.org/10.1016/j.omtm.2024.101375

Vancouver

Liefhebber JMP, Brasser G, Spronck EA, Ottenhoff R, Paerels L, Ferraz MJ, et al. Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease. Molecular Therapy - Methods & Clinical Development. 2024;32(4):101375. doi:10.1016/j.omtm.2024.101375

BibTeX
@article{Liefhebber2024,
  author = {Liefhebber, Jolanda M P and Brasser, Giso and Spronck, Elisabeth A and Ottenhoff, Roelof and Paerels, Lieke and Ferraz, Maria J and Schwarz, Lukas K and Efthymiopoulou, Nikoleta and Kuo, Chi-Lin and Montenegro-Miranda, Paula S and Evers, Melvin M and Aerts, Johannes M F G and Liu, Ying Poi},
  title = {Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease},
  journal = {Molecular Therapy - Methods & Clinical Development},
  year = {2024},
  volume = {32},
  number = {4},
  pages = {101375},
  doi = {10.1016/j.omtm.2024.101375}
}
Kostenlos starten →